We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Brain Cancer

Journal Scan / Research · February 01, 2021

Very Low Mutation Burden Is a Feature of Inflamed Recurrent Glioblastomas Responsive to Cancer Immunotherapy

Nature Communications

 

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Communications
Very Low Mutation Burden Is a Feature of Inflamed Recurrent Glioblastomas Responsive to Cancer Immunotherapy
Nat Commun 2021 Jan 13;[EPub Ahead of Print], M Gromeier, MC Brown, G Zhang, X Lin, Y Chen, Z Wei, N Beaubier, H Yan, Y He, A Desjardins, JE Herndon, FS Varn, RG Verhaak, J Zhao, DP Bolognesi, AH Friedman, HS Friedman, F McSherry, AM Muscat, ES Lipp, SK Nair, M Khasraw, KB Peters, D Randazzo, JH Sampson, RE McLendon, DD Bigner, DM Ashley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading